Please login to bookmarkClose

A commission baked into a funding agreement in a class action against Mayne Pharma is under threat, with a judge mulling an order off his own bat to cut the rate. 

Subscribe to Lawyerly to access this article.

Already a subscriber?
Lost your password?
error: The content is secured.

For information on rights and reprints, contact subscriptions@lawyerly.com.au